RESUMO
Background: The current study sought to assess restoration of carbohydrate metabolism in known type 2 diabetes patients to achieve good glycemic control without dependency on oral antihyperglycemic agents by implementing the comprehensive diabetes control (CDC) program. Methods: A retrospective, single-centre observational study was conducted from April 2021 to April 2022. Patients who were known cases of type 2 diabetes mellitus aged 18 years and above who underwent at least 6 sessions of the CDC program were included in this study. Patients with type 1 diabetes mellitus were excluded from the study. Follow-up was conducted after 90 days. Baseline data was compared with follow-up data. Results: A total of 69 patients were assessed in this study. Of the patients, testing was performed on 95.8% patients, of which. 92.8% patients were found to have negative glucose tolerance and 7.3% were found to have impaired glucose tolerance. Conclusions: The CDC program can be useful to restore euglycemia in know type 2 diabetic patients by reducing insulin resistance caused by central obesity.
RESUMO
Background: Diabetes mellitus, in particular, has emerged as a significant health concern, affecting millions of individuals and placing a considerable strain on the healthcare system. Promoting remission of diabetes, wherein patients achieve a state of sustained blood sugar control without the need for ongoing medication or with a reduced reliance on medication, can yield remarkable benefits. This study sought to understand the role of Aahar and Panchakarma on restoration of euglycemia in known type 2 diabetes patients. Methods: A retrospective, observational, cohort study was conducted at Madhavbaug Cardiac Care Clinic between April 2021 and April 2022 in Maharashtra, India. Patients aged 18 years and older with a diagnosis of type 2 diabetes mellitus with glycated haemoglobin level (HbA1c) >7% and had participated in the Comprehensive Diabetes Care (CDC) program were included in this study. Parameters such as HbA1c, body weight, body mass index (BMI), and dependence on conventional allopathic medication were assessed at the end of the CDC program. Follow-up was conducted at 90 days. Day 1 and day 90 data were compared. Results: Of the 45 patients, 17 (40.5%) patients had a negative glucose tolerance and 14 (33.3%) patients had impaired glucose tolerance. HbA1c, body weight, and BMI improved at the end of CDC program. Dependency on conventional allopathic medications was also reduced. Conclusions: Restoration of euglycemia in patients with type 2 diabetes mellitus is possible, however, further studies to understand the affecting factors are warranted.